Latest Cancer vaccine Stories

Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer

2013-01-31 08:29:57

OSLO, January 31, 2013 /PRNewswire/ -- 18-24 patients will be included in the clinical Phase I/II study. Results from the Phase I part are expected in first half of 2013. Principal investigator and oncologist Svein Dueland states: "It is exciting that we now recruit patients for this study, which originates from collaboration between Oslo University Hospital and Norsk Hydro. Participation in clinical trials is an important part of the treatment we can offer cancer...

Generex Announces Details of Investor Conference Call

2013-01-29 12:27:06

WORCESTER, Mass. and TORONTO, Jan. 29, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) previously announced that Company management has scheduled an investor conference call for Thursday, January 31, 2013. Today, the Company provided the following information for access to the conference call: <blockquote> Date of Call: Thursday, January 31, 2013 Time of Call: 10 a.m. EST Participant Operator Assisted Toll-Free Dial-In Number: (877)...

NW Bio Presenting At Phacilitate Cell Therapy Forum

2013-01-29 08:30:41

BETHESDA, Md., Jan. 29, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for cancer, announced today that Dr. Marnix Bosch, the Company's Chief Technical Officer, will be presenting at the Phacilitate Cell And Gene Therapy Forum 2013, today at 3:30 pm in a session entitled Clinical Development Updates: Oncology. The conference is being held at the Grand Hyatt Hotel at 10(th) and H...

Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.

2013-01-22 12:27:30

TSX Venture: QPT EDMONTON, Jan. 22, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has achieved 50% accrual having enrolled the 40(th) patient in its ongoing 80 patient Phase II Oregovomab front-line chemo-immunotherapy clinical trial in Italy and the U.S. The objective of this study is to confirm that optimally dosed oregovomab in...

Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.

2013-01-22 08:27:30

SEATTLE, Jan. 22, 2013 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) is pleased to announce the January publication of a paper titled "Enzymatic Discovery of a HER-2/neu Epitope That Generates Cross-Reactive T-cells", authored by Henle et al, J.Immunol. (2013), 190, 479-488. This work, performed in the laboratory of Dr Keith Knutson at Mayo Clinic, describes the discovery of a novel HER-2/neu Class I epitope (p373-382) TapImmune has licensed from Mayo Clinic for the development of...

Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study

2013-01-15 07:18:15

DURHAM, N.C., Jan. 15, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, announced that the first patients have been enrolled in the ADAPT Phase 3 clinical study for AGS-003, its most advanced product candidate. AGS-003 is an investigational, fully personalized, dendritic-cell...

Generex Announces Investor Conference Call

2013-01-11 08:22:02

WORCESTER, Mass. and TORONTO, Jan. 11, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today announced that Company management has scheduled an investor conference call for Thursday, January 31, 2013. The purpose of the call is to provide the Company's stockholders with a review of recent Company activity and management's go-forward plans. The discussion will include: the clinical and regulatory status of the AE37 breast cancer vaccine and business development...

Positive Interim Safety Analysis Achieved in Breast Cancer Patients Treated with HER2/neu Antigens

2013-01-09 08:27:41

SEATTLE, Jan. 9, 2013 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events. As a result treatment of the remaining 17 patients in the Phase I study, being conducted at Mayo Clinic, Rochester, MN will progress. The proprietary HER2/neu Class II antigens, discovered by Keith Knutson Ph.D. and...

Cancer Cells Co-Opt Immune Response To Escape Destruction

2012-12-19 11:28:22

Researchers at the University of California, San Diego School of Medicine report that tumor cells use stress signals to subvert responding immune cells, exploiting them to actually boost conditions beneficial to cancer growth. The findings are published in the December 18 online issue of the journal PLOS ONE. Lead author Navin R. Mahadevan, a graduate student in the Laboratory of Immunology at the UC San Diego Moores Cancer Center, and colleagues found that tumor cells manipulate a...

MabVax Therapeutics Receives SBIR Program Award From The National Cancer Institute To Manufacture Clinical Supplies For Phase 2 Neuroblastoma Trial

2012-12-18 08:27:26

SAN DIEGO, Dec. 18, 2012 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI). The initial grant award of $150,000 will support the manufacture and testing of the company's neuroblastoma...